Canada Markets closed

Agile Therapeutics, Inc. (AGRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5849-0.0151 (-2.52%)
At close: 04:00PM EST
0.5998 +0.01 (+2.55%)
After hours: 07:44PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.6000
Open0.6105
Bid0.5800 x 1100
Ask0.5998 x 2900
Day's Range0.5651 - 0.6150
52 Week Range0.5400 - 3.7700
Volume1,663,028
Avg. Volume2,021,426
Market Cap51.625M
Beta (5Y Monthly)1.02
PE Ratio (TTM)N/A
EPS (TTM)-0.6990
Earnings DateFeb. 28, 2022 - Mar. 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • Zacks

    Agile Therapeutics (AGRX) Reports Q3 Loss, Lags Revenue Estimates

    Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 5.26% and -13.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Agile Therapeutics Reports Third Quarter 2021 Financial Results

    Prescription Demand Growth Continues in the Third Quarter 2021 with a 61% Increase in Twirla Cycles Dispensed Twirla Refill Rates Continue to Grow by 86% in Third Quarter 2021 Company Advances Programs Focused on Increasing Demand for Twirla Management to Host Conference Call Today, Tuesday, November 2, 2021 at 4:30 p.m. EDT PRINCETON, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three mont

  • GlobeNewswire

    Agile Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on Tuesday, November 2, 2021

    Live Conference Call and Webcast at 4:30 p.m. ETPRINCETON, N.J., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it will report third quarter 2021 financial results after the market close on Tuesday, November 2, 2021 as follows: DateTuesday, November 2, 2021Time4:30 p.m. ETWebcast (live and archived)Events & PresentationsDial-in numbers(833) 979-2857 (U.S. toll-free) or (236) 714-2948Conference ID9988403 Investors intereste